Russia has developed an artificial intelligence solution to accelerate drug development. Thanks to this, the time it takes to bring new drugs to market can be reduced three times.
Subscribe to RB.RU on Telegram
Sberbank and R-Pharm have developed an artificial intelligence-based solution that can accelerate drug development. This was reported by the press service of Sberbank and a press release was also published on the R-Pharm website.
Companies have created artificial intelligence technology to generate antibodies that, in particular, can reduce the development of molecules with the required characteristics to two months. Together with other technological solutions, the development time of molecules in the future will be reduced three times.
“The AI technologies that we are introducing at certain stages of drug development will ensure a significant reduction in time” from laboratory to patient “and a reduction in costs, making medicines more accessible,” said Alexander Bykov , director of health care. economics at R-Pharm.
In February 2021, Sberbank, together with R-Pharm, invested in Sber Pharmacy and received 45% of the company. The amount of Sberbank’s investments amounted to 5.7 billion rubles.
Author:
Kirill Bilyk
Source: RB
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
